180 Wealth Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.15M | Buy |
47,953
+506
| +1% | +$13.2K | 0.12% | 185 |
|
|
2026
Q1 | $1.33M | Sell |
47,447
-43
| -0.1% | -$1.15K | 0.15% | 147 |
|
|
2025
Q4 | $1.18M | Buy |
47,490
+1,365
| +3% | +$34.4K | 0.13% | 156 |
|
|
2025
Q3 | $1.18M | Sell |
46,125
-72
| -0.2% | -$1.78K | 0.14% | 147 |
|
|
2025
Q2 | $1.12M | Buy |
46,197
+4,526
| +11% | +$106K | 0.16% | 138 |
|
|
2025
Q1 | $1.06M | Buy |
41,671
+5,657
| +16% | +$148K | 0.17% | 128 |
|
|
2024
Q4 | $955K | Buy |
36,014
+4,805
| +15% | +$130K | 0.15% | 132 |
|
|
2024
Q3 | $903K | Sell |
31,209
-215
| -0.7% | -$6.27K | 0.14% | 149 |
|
|
2024
Q2 | $901K | Buy |
31,424
+2,935
| +10% | +$80.8K | 0.15% | 139 |
|
|
2024
Q1 | $791K | Buy |
28,489
+857
| +3% | +$23.8K | 0.14% | 148 |
|
|
2023
Q4 | $821K | Sell |
27,632
-5,572
| -17% | -$168K | 0.16% | 126 |
|
|
2023
Q3 | $1.1M | Buy |
33,204
+404
| +1% | +$14.3K | 0.25% | 102 |
|
|
2023
Q2 | $1.2M | Sell |
32,800
-364
| -1% | -$14.2K | 0.26% | 97 |
|
|
2023
Q1 | $1.35M | Sell |
33,164
-2,410
| -7% | -$104K | 0.31% | 87 |
|
|
2022
Q4 | $1.57M | Sell |
35,574
-2,866
| -7% | -$137K | 0.37% | 81 |
|
|
2022
Q3 | $1.68M | Buy |
38,440
+1,777
| +5% | +$86.3K | 0.46% | 65 |
|
|
2022
Q2 | $1.92M | Sell |
36,663
-3,122
| -8% | -$159K | 0.49% | 59 |
|
|
2022
Q1 | $2M | Sell |
39,785
-1,522
| -4% | -$79K | 0.44% | 63 |
|
|
2021
Q4 | $2.18M | Sell |
41,307
-5,258
| -11% | -$261K | 0.49% | 56 |
|
|
2021
Q3 | $1.93M | Sell |
46,565
-431
| -0.9% | -$19.1K | 0.43% | 63 |
|
|
2021
Q2 | $2.27M | Sell |
46,996
-1,661
| -3% | -$64.6K | 0.52% | 46 |
|
|
2021
Q1 | $1.94M | Buy |
48,657
+248
| +0.5% | +$8.8K | 0.48% | 60 |
|
|
2020
Q4 | $1.78M | Buy |
48,409
+4
| +0% | +$147 | 0.51% | 52 |
|
|
2020
Q3 | $1.72M | Buy |
48,405
+317
| +0.7% | +$11.1K | 0.65% | 36 |
|
|
2020
Q2 | $1.65M | Sell |
48,088
-351
| -0.7% | -$11.9K | 0.66% | 35 |
|
|
2020
Q1 | $1.51M | Sell |
48,439
-6,509
| -12% | -$222K | 0.78% | 26 |
|
|
2019
Q4 | $2.12M | Sell |
54,948
-2,437
| -4% | -$86.8K | 0.85% | 22 |
|
|
2019
Q3 | $1.97M | Sell |
57,385
-4,311
| -7% | -$157K | 0.87% | 25 |
|
|
2019
Q2 | $2.24M | Buy |
61,696
+1,151
| +2% | +$45.7K | 1.01% | 19 |
|
|
2019
Q1 | $2.35M | Sell |
60,545
-5,786
| -9% | -$232K | 1.06% | 18 |
|
|
2018
Q4 | $2.77M | Sell |
66,331
-802
| -1% | -$33.3K | 1.29% | 10 |
|
|
2018
Q3 | $2.81M | Buy |
67,133
+2,800
| +4% | +$108K | 1.3% | 10 |
|
|
2018
Q2 | $2.21M | Sell |
64,333
-14,303
| -18% | -$489K | 1.1% | 16 |
|
|
2018
Q1 | $2.65M | Sell |
78,636
-3,456
| -4% | -$119K | 1.38% | 11 |
|
|
2017
Q4 | $2.82M | Buy |
+82,092
| New | +$2.8M | 1.44% | 13 |
|
Other funds holding PFE
180 Wealth Advisors's PFE Position: Q2 2026 in Review
180 Wealth Advisors increased its Pfizer (PFE) stake by 1.1% in Q2 2026, buying an estimated $13.2K and bringing the position to 47,953 shares worth $1.15M. The position accounts for 0.12% of the portfolio, ranked #185.
180 Wealth Advisors first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $2.82M in Q4 2017. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- 180 Wealth Advisors held 47,953 shares of Pfizer worth $1.15M as of Q2 2026.
- 180 Wealth Advisors bought 506 Pfizer shares in Q2 2026, an estimated $13.2K.
- Pfizer made up 0.12% of 180 Wealth Advisors's portfolio in Q2 2026, its #185 holding.
- 180 Wealth Advisors first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- 180 Wealth Advisors's Pfizer position peaked at $2.82M in Q4 2017.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on 180 Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.